Recently Added Drugs
1. Agamree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12201639 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
2. Akynzeo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208109 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: NA
Dosage: POWDER; SOLUTION
How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage
AKYNZEO family patents
3. Augtyro patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12187739 | BRISTOL | Diaryl macrocycle polymorph |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| ODE*(ODE*) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-483) | Jun 13, 2031 |
| Orphan Drug Exclusivity(ODE-488) | Jun 13, 2031 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
AUGTYRO family patents
4. Brynovin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11944621 | AZURITY | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(15 years from now) | |
Drugs and Companies using SITAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
BRYNOVIN family patents
5. Copiktra patent expiration
Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213983 | SECURA | Treatment of cancers using PI3 kinase isoform modulators |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE
More Information on Dosage
COPIKTRA family patents
6. Emblaveo patent expiration
EMBLAVEO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7112592 | ABBVIE | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(8 months from now) | |
| US8471025 | ABBVIE | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(6 years from now) | |
| US8969566 | ABBVIE | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | |
| US9284314 | ABBVIE | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | |
| US9695122 | ABBVIE | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ABBVIE | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(1 year, 6 months from now) | |
| US8835455 | ABBVIE | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(5 years from now) | |
Drugs and Companies using AVIBACTAM SODIUM; AZTREONAM ingredient
Market Authorisation Date: 07 February, 2025
Treatment: Treatment of complicated intra-abdominal bacterial infections in adult patients
Dosage: POWDER
More Information on Dosage
EMBLAVEO family patents
7. Evrysdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(7 years from now) | |
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(10 years from now) | |
| US12122789 | GENENTECH INC | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
Apr, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11827646 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Jan, 2036
(10 years from now) | |
| US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of spinal muscular atrophy
Dosage: TABLET
More Information on Dosage
EVRYSDI family patents
8. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213988 | ASTRAZENECA AB | Methods of treating chronic kidney disease with dapagliflozin |
Apr, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Reducing the risk of sustained egfr decline, end-stage kidney disease, cv death, and hospitalization for heart failure in adults with ckd at risk of progression and without type ii diabetes after at l...
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
9. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11066358 | SPRINGWORKS | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| US11084780 | SPRINGWORKS | Door construction |
Feb, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11453641 | SPRINGWORKS | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US11571402 | SPRINGWORKS | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| US11806321 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(15 years from now) | |
| US11819487 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US12011424 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US12037306 | SPRINGWORKS | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US12090128 | SPRINGWORKS | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof |
Feb, 2041
(15 years from now) | |
| US11806322 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11839595 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11883375 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12220390 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12029711 | SPRINGWORKS | Dosage forms of mirdametinib |
Mar, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection; Treatment o...
Dosage: CAPSULE
More Information on Dosage
GOMEKLI family patents
10. Grafapex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7199162 | MEDEXUS | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
Oct, 2025
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2030 |
Drugs and Companies using TREOSULFAN ingredient
NCE-1 date: 21 January, 2029
Market Authorisation Date: 21 January, 2025
Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation
Dosage: POWDER
More Information on Dosage
GRAFAPEX family patents
11. Hetlioz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12201604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24-hour sleep-wake disorder by administering tasimelteon
Dosage: CAPSULE
How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage
HETLIOZ family patents
12. Hetlioz Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12201604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION
More Information on Dosage
HETLIOZ LQ family patents
13. Idose Tr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12201557 | GLAUKOS | Drug eluting ocular implant and method of treating an ocular disorder |
Jun, 2030
(5 years from now) | |
| US12201555 | GLAUKOS | Drug eluting ocular implant |
Feb, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 13 December, 2023
Treatment: Method of lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: IMPLANT
More Information on Dosage
IDOSE TR family patents
14. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12201690 | PHARMACYCLICS LLC | Formulations/compositions comprising ibrutinib |
Jun, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2030 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 24 August, 2022
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
15. Inzirqo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11878022 | NOVITIUM PHARMA | Hydrochlorothiazide compositions |
Jan, 2044
(18 years from now) | |
Drugs and Companies using HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 28 January, 2025
Treatment: Treatment of hypertension in patients who are in need of an oral liquid suspension of hydrochlorothiazide
Dosage: FOR SUSPENSION
More Information on Dosage
INZIRQO family patents
16. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
17. Jaypirca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12220401 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
| Orphan Drug Exclusivity(ODE-424) | Jan 27, 2030 |
| Orphan Drug Exclusivity(ODE-451) | Dec 01, 2030 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor
Dosage: TABLET
More Information on Dosage
JAYPIRCA family patents
18. Journavx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11834441 | VERTEX PHARMS INC | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
Drugs and Companies using SUZETRIGINE ingredient
NCE-1 date: 30 January, 2029
Market Authorisation Date: 30 January, 2025
Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine
Dosage: TABLET
More Information on Dosage
JOURNAVX family patents
19. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8410274 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US8754224 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US9670163 (Pediatric) | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US7495103 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
|
US8324242 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Feb, 2028
(2 years from now) | |
|
US10646481 (Pediatric) | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US11564916 (Pediatric) | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 20 May, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
20. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8410274 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US8754224 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US9670163 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US7495103 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
|
US8324242 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Feb, 2028
(2 years from now) | |
|
US10646481 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US11564916 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
| US12214083 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Treatment of cf in a patient age 1 month to <4 months who has in the cftr gene at least one responsive mutation based on clinical and/or in vitro assay data using the composition recited in claim 1 of...
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
21. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12220403 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
22. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138351 | JANSSEN BIOTECH | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Apr, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
23. Lenvima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226409 | EISAI INC | Treatment of hepatocellular carcinoma |
May, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: First-line treatment of patients with unresectable hepatocellular carcinoma (hcc) using dosage modifications for adverse reactions
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
24. Livtencity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213989 | TAKEDA PHARMS USA | Use of maribavir in treatment regimens |
Nov, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treating post-transplant cmv infection/disease refractory to ganciclovir, valganciclovir, cidofovir or foscarnet by administering 1200 mg maribavir twice daily, where the patient is concomitantly expo...
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
25. Lodoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233035 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin |
Nov, 2033
(8 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: A method of treating and/or reducing the risk of a cardiovascular event in a patient
Dosage: TABLET
More Information on Dosage
LODOCO family patents
26. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226377 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
27. Myhibbin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226526 | AZURITY | Mycophenolate oral suspension |
Aug, 2039
(14 years from now) | |
Drugs and Companies using MYCOPHENOLATE MOFETIL ingredient
Market Authorisation Date: 01 May, 2024
Treatment: Prophylaxis of organ rejection
Dosage: SUSPENSION
More Information on Dosage
MYHIBBIN family patents
28. Nextstellis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233074 | MAYNE PHARMA | Contraceptive methods with improved pearl index |
Feb, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 15 April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET
More Information on Dosage
NEXTSTELLIS family patents
29. Norliqva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226528 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(15 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina
Dosage: SOLUTION
More Information on Dosage
NORLIQVA family patents
30. Orkambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7973038 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
|
US8741933 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
|
US9216969 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
|
US8410274 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US8754224 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US9670163 (Pediatric) | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US9931334 (Pediatric) | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Jun, 2027
(2 years from now) | |
|
US7495103 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
|
US8324242 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Feb, 2028
(2 years from now) | |
|
US10076513 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Jun, 2029
(4 years from now) | |
|
US10597384 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(4 years from now) | |
|
US11052075 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Jun, 2029
(4 years from now) | |
|
US12065432 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(4 years from now) | |
|
US8653103 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Jun, 2029
(4 years from now) | |
|
US9150552 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(4 years from now) | |
|
US8846718 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jan, 2030
(4 years from now) | |
|
US10646481 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US11564916 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2030
(4 years from now) | |
|
US9192606 (Pediatric) | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Mar, 2030
(4 years from now) | |
|
US8507534 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Mar, 2031
(5 years from now) | |
|
US8716338 (Pediatric) | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Mar, 2031
(5 years from now) | |
|
US8993600 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 02, 2025 |
| Pediatric Exclusivity(PED) | Jun 13, 2028 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| M(M-218) | Jan 25, 2021 |
| New Product(NP) | Aug 07, 2021 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Strength(NS) | Sep 02, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| M(M-14) | Dec 13, 2027 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: NA
Dosage: TABLET; GRANULE
More Information on Dosage
ORKAMBI family patents
31. Pluvicto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208102 | NOVARTIS | Methods of treating cancer |
Sep, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...
Dosage: SOLUTION
More Information on Dosage
PLUVICTO family patents
32. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233105 | ANI PHARMS | Methods for storing and warming purified corticotropin compositions |
Oct, 2043
(18 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
33. Qinlock patent expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12226406 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
34. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9181223 | DECIPHERA PHARMS | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103507 | DECIPHERA PHARMS | Methods of treating disorders using CSF1R inhibitors |
Feb, 2040
(14 years from now) | |
| US11679110 | DECIPHERA PHARMS | Methods of treating disorders using CSF1R inhibitors |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: Treatment of tenosynovial giant cell tumor
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
35. Rybelsus patent expiration
RYBELSUS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(6 years from now) | |
| US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(6 years from now) | |
| US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
36. Sohonos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12201614 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasis (myositis) ossificans progressiva
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
37. Suflave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12239659 | BRAINTREE LABS | Methods of administering safe colon cleansing compositions |
Jun, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 15, 2026 |
Market Authorisation Date: 15 June, 2023
Treatment: Gastrointestinal flavored solution indicated for cleansing the colon in preparation for colonoscopy
Dosage: FOR SOLUTION
More Information on Dosage
SUFLAVE family patents
38. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12209059 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
39. Symbravo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10029010 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10058614 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10137131 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10195278 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10265324 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10363312 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10369224 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10426839 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10463736 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10471014 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10471069 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10512692 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10512693 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10517950 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10532101 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10537642 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10561664 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10583144 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10653777 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10688102 | AXSOME | Combination treatment for migraine and other pain |
Apr, 2036
(10 years from now) | |
| US10688185 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10695429 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10695430 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10702535 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10702602 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10722583 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10729696 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10729697 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10729773 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10758617 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10758618 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10780165 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10780166 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10799588 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10821181 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10821182 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10894053 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10905693 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10918722 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10933136 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10933137 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10940153 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US10987358 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11013805 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11013806 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11020483 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11045549 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11135295 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11207328 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11219626 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11285213 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11331323 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11369684 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11426414 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11471464 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11471465 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11504429 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11510927 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11571428 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11602563 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11607456 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11617755 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11617756 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11617791 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11628173 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11712441 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11738085 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11759522 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11801250 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11806354 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11826370 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US11865117 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US9821075 | AXSOME | Pharmaceutical compositions comprising meloxicam |
Apr, 2036
(10 years from now) | |
| US12128052 | AXSOME | Pharmaceutical compositions comprising meloxicam |
May, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2028 |
Drugs and Companies using MELOXICAM; RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 30 January, 2025
Treatment: Reducing tmax of orally administered meloxicam; Acute treatment of migraine; Rapid delivery of meloxicam to the blood of a human being; Improving oral bioavailability of meloxicam; Acute treatment of ...
Dosage: TABLET
More Information on Dosage
SYMBRAVO family patents
40. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12214083 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| M(M-313) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cf in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a responsive mutation based on clinical and/or in vitro data comprising administering a compos...
Dosage: GRANULES
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
41. Vitrakvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337967 | BAYER HLTHCARE | Methods of treatment |
May, 2037
(12 years from now) | |
| US11974998 | BAYER HLTHCARE | Methods of treatment |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Treatment of solid tumors that have a ntrk gene fusion through coadministration of larotrectinib with posaconazole, by discontinuing posaconazole and waiting 3 to 5 of its half-lives, before administe...
Dosage: CAPSULE
More Information on Dosage
VITRAKVI family patents
42. Vitrakvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337967 | BAYER HEALTHCARE | Methods of treatment |
May, 2037
(12 years from now) | |
| US11974998 | BAYER HEALTHCARE | Methods of treatment |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Treatment of solid tumors that have a ntrk gene fusion through coadministration of larotrectinib with posaconazole, by discontinuing posaconazole and waiting 3 to 5 of its half-lives, before administe...
Dosage: SOLUTION
More Information on Dosage
VITRAKVI family patents
43. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12214017 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
44. Xdemvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12213964 | TARSUS | Isoxazoline parasiticide formulations |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
45. Xeljanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 06 November, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
46. Xeljanz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
47. Xeljanz Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(1 year, 1 month from now) | |
|
US11253523 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(9 years from now) | |
|
US9937181 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(9 years from now) | |
|
US10639309 (Pediatric) | PFIZER | Tofacitinib oral sustained release dosage forms |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage
XELJANZ XR family patents
48. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12220409 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Jul 09, 2027 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 09 July, 2024
Treatment: NA
Dosage: FOAM; CREAM
More Information on Dosage
ZORYVE family patents
49. Zunveyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208176 | ALPHA COGNITION | Process for making dry and stable hemostatic compositions |
Feb, 2044
(18 years from now) | |
Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient
Market Authorisation Date: 26 July, 2024
Treatment: Treatment of mild to moderate dementia of the alzheimer's type
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
ZUNVEYL family patents